Group 1: Project and Investment Updates - The company has not arranged for the construction of the erythritol project and has no related information to provide at this time [1] - The company has completed fundraising but has no specific plans for the erythritol project, nor a timeline for construction [1] - The company is focusing on existing projects and has no further restructuring plans [2] Group 2: Market and Trade Impact - The trade war has not affected the company's export products, and export volumes remain stable [1] - The company has implemented price increases in the U.S. market to cover tariff costs [1] - The company maintains a stable market share globally, despite fluctuations in international trade [1] Group 3: Product Performance and Sales - The company's chemical drug product, Jinmeisu, has maintained a high reputation and stable supply-demand relationship in the market [2] - The main vaccine product, Blue Ear Inactivated Vaccine, continues to hold the number one market share [2] - The company’s new production capacity for chemical drugs is currently at 100% utilization [2] Group 4: Future Development Strategies - The company aims to enhance product quality, innovation capabilities, and market share to ensure steady profit growth [2] - The company is actively pursuing strategic development goals and aims to achieve a market value of 20 billion [3] - The company is exploring new avenues in the animal health sector while focusing on existing product development [2] Group 5: Financial and Operational Insights - The company’s logistics costs for the first half of 2025 are still being compiled, with details to be disclosed in the upcoming half-year report [5] - The company has invested 158 million in a wastewater treatment project to enhance its capabilities and profitability [4] - The company is closely monitoring the impact of corn price fluctuations on product costs and adjusting procurement strategies accordingly [4]

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., forecasts a significant increase in net profit for the first half of 2025, driven by new product launches and strong sales in pet-related products [1][4]. Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 107 million yuan and 122 million yuan, representing a year-on-year increase of 44.70% to 64.98% [2][4]. - The forecasted net profit, excluding non-recurring gains and losses, is anticipated to be between 93 million yuan and 106 million yuan, reflecting a year-on-year increase of 40.05% to 59.63% [2][4]. Previous Year Performance - In the same period last year, the net profit attributable to shareholders was 73.9463 million yuan, and the net profit after excluding non-recurring gains and losses was 66.4035 million yuan [2]. Reasons for Performance Increase - The launch of new products, such as the joint vaccine, has contributed to new growth points for the company. Sales revenue from pet-related products continues to show high growth [2]. - The company is focusing on marketing system reform, strengthening process management, and ensuring performance implementation to meet sales targets amid intense market competition [2]. - Lean production management has optimized unit costs, and enhanced control over sales expenses has been implemented to achieve high-quality and efficient development goals [2].

Group 1: Investment Opportunities - The article highlights three dividend growth stocks that are currently undervalued, with share prices down between 19% and 26% from their highs, presenting a buying opportunity for investors [2][3] Group 2: Zoetis - Zoetis is a leading company in the animal healthcare industry, offering a variety of products including medicines and vaccines, and has outperformed the S&P 500 since its IPO in 2013 [3][4] - The company's valuation peaked at an average of 47 times free cash flow (FCF) over the last decade, but has now adjusted to a more reasonable 31 times FCF, with a dividend yield of 1.2% [4][5] - Zoetis has a return on invested capital (ROIC) of 22%, indicating strong growth potential through new product introductions and lifecycle innovations [7] - The company has achieved a 28% growth in FCF and an 18% increase in dividend payments annually over the last decade, making it a strong compounder [8] - Recent sales growth in parasiticides, dermatology, and pain products exceeding 10% suggests continued rewards for dividend investors [9] Group 3: Pool Corp. - Pool Corp. is the largest distributor of pool products globally and has seen significant growth since its IPO in 1995, but its share price has stagnated recently due to economic factors [11] - The company generates 64% of its sales from non-discretionary maintenance and repair, providing stability amid cyclical downturns [12] - Despite challenges, Pool Corp. generated nearly $500 million in FCF last year and has utilized this to repurchase shares, with its stock down 23% from year-long highs [13] - The company has an average ROIC of 18%, demonstrating its ability to navigate economic cycles profitably [14] - Pool Corp. currently offers a 1.6% dividend yield, the highest since 2012, with only 38% of FCF used for dividends, indicating potential for future growth [15] Group 4: Old Dominion Freight Line - Old Dominion Freight Line specializes in less-than-truckload (LTL) hauling and has been a strong performer since its IPO in 1991, though it is also subject to cyclical fluctuations [16][18] - The company has experienced a 26% drop in stock price due to a freight industry recession and weak industrial shipments [18] - Old Dominion boasts a leading ROIC, allowing it to gain market share and repurchase shares during economic downturns [20] - The company has reduced its share count by more than one-sixth over the last decade, and while its dividend yield is currently 0.6%, it has grown by 33% over the past five years, utilizing only 27% of FCF [21]

Investment Rating - The industry investment rating is "Overweight" indicating that the industry is expected to outperform the overall market [2][45]. Core Insights - The report highlights a significant increase in pig prices, reaching a new high since the Spring Festival, with a current average price of 15.37 CNY/kg, up 4.8% week-on-week [3][4]. - The report emphasizes the importance of focusing on quality pig farming companies and the opportunities in the livestock support and pet food sectors, as the pet food industry remains vibrant with leading brands performing well [3][4]. - The report anticipates a notable improvement in overall profitability in the agricultural sector for the first half of 2025, particularly in pig farming, feed, pet food, and animal health sectors [3][4]. Summary by Sections Market Performance - The Shenwan Agricultural, Forestry, Animal Husbandry, and Fishery Index rose by 2.5%, outperforming the CSI 300 Index which increased by 1.5% [3][4]. - The top five gainers in individual stocks include Muyuan Foods (+4.9%), Shennong Group (+4.0%), and Xiaoming Co. (+4.8%) [3][4]. Pig Farming - Pig prices have shown a strong upward trend, with the average price reaching 15.37 CNY/kg, marking a significant increase from previous months [3][4]. - The report discusses the reasons behind the recent price surge, including a reduction in supply pressure and increased second fattening activities [3][4]. Poultry Farming - The report notes a decline in broiler chick prices, with the average price dropping to 1.14 CNY/chick, down 7.3% week-on-week [3][4]. - Broiler prices have also decreased, with the average price for live chickens at 3.37 CNY/kg, reflecting a weak market [3][4]. Animal Health - The report highlights a recovery in demand for vaccines, with a 15.8% year-on-year increase in vaccine issuance from January to May 2025 [3][4]. - It emphasizes the importance of monitoring new vaccine varieties and the potential growth in the pet health sector [3][4]. Recommendations - The report suggests focusing on companies such as Muyuan Foods, Wen's Food Group, and Shennong Group for potential investment opportunities [3][4].

Investment Rating - The report rates the agricultural, forestry, animal husbandry, and fishery industry as "Overweight" due to expected overall profit improvement in the sector [3][4]. Core Insights - The report highlights that the profitability of pig farming is expected to improve, with a stable pig price and a significant increase in average profit per head for self-bred pigs [4]. - Poultry farming shows a mixed outlook, with white chicken prices bottoming out and yellow chicken profitability declining, while egg-laying chicks continue to experience high demand [4]. - The pet food sector is projected to maintain high growth, with leading companies showing strong online sales growth, despite a decline in exports to the U.S. due to tariffs [4]. - Animal health is recovering, with increased demand for vaccines and improved sales of veterinary preparations [4]. - The seed industry faces challenges with declining corn prices and increased competition, leading to pressure on the performance of leading seed companies [4]. Summary by Sections Pig Farming - The average price of pigs in H1 2025 is expected to be 14.80 CNY/kg, a decrease of 4.2% year-on-year, while the average profit for self-bred pigs is projected at 69.04 CNY/head, recovering from a loss of 24.82 CNY/head in H1 2024 [4]. Poultry Farming - White chicken prices are under pressure due to oversupply, with the average price for commodity broiler chicks at 2.4 CNY/bird, down 21% year-on-year. Yellow chicken prices are also declining, with the average price for Qingjiao chicken at 8.9 CNY/kg, down 19% year-on-year [4]. Pet Food - The domestic pet food market is experiencing a growth rate of 17% in online GMV for the first five months of 2025, compared to 14% in the same period of 2024. Leading companies like Guibao Pet and Zhongchong Co. show growth rates of 51% and 26%, respectively [4]. Animal Health - The demand for veterinary vaccines has increased, with a 15.8% year-on-year rise in vaccine approvals in the first five months of 2025. Prices for veterinary preparations like Tylosin and Tiamulin have increased by 39.8% and 9.3%, respectively [4]. Seed Industry - The corn seed market is under pressure due to falling corn prices and high competition, leading to a decline in seed prices and performance expectations for leading seed companies [4].

Summary of the Conference Call on the Pet Pharmaceutical Industry Industry Overview - The pet pharmaceutical market in China is experiencing rapid growth, with a compound annual growth rate (CAGR) of 22%, driven by rigid demand throughout the pet lifecycle [1][2] - The aging pet population is increasing, with the proportion of senior dogs over seven years old rising significantly, leading to higher demand for medications for age-related diseases [1][2] Key Insights - The market size is projected to grow from less than 9.4 billion yuan in 2020 to nearly 21 billion yuan by 2024, indicating a robust growth trajectory [2] - The demand for pet medications is characterized by its rigidity, affecting various age groups, with high incidence rates of conditions like dental calculus and skin diseases [2] - The industry faces supply bottlenecks, particularly in medications for elderly diseases, which are heavily reliant on imports [4] Supply Chain and Innovation - The industry is exploring human drug conversion to alleviate supply-demand conflicts, exemplified by the release of a directory of urgently needed human medications for pets [4] - There is a push for accelerated research and innovation to develop effective treatments for chronic diseases and tumors, with the first domestic monoclonal antibody drug clinical approval achieved in June [4] Progress in Domestic Vaccine Development - Domestic companies have made significant strides in the core vaccine sector, particularly with the launch of the first approved domestic cat trivalent vaccine by Ruipuhua in January 2024 [5][6] - By June 2025, a total of 11 domestic cat trivalent vaccines are expected to be on the market, breaking the monopoly previously held by foreign companies [5][6] Market Dynamics - The pet vaccine market is vast, with the mandatory rabies vaccine market valued at approximately 3-4 billion yuan, and both cat and dog trivalent vaccines around 2 billion yuan each [6] - Domestic vaccines have advantages in strain matching and pricing, typically being 20% cheaper than imported alternatives [7] Competitive Landscape - The cat trivalent vaccine market remains in a blue ocean state, with less than 10% immunization penetration among urban pet cats, indicating significant growth potential [8][9] - Over 10 domestic companies are involved in the pet vaccine sector, including traditional veterinary medicine firms and those transitioning from human pharmaceuticals [10] Challenges and Future Trends - Domestic companies face challenges in channel development, needing to overcome the premium pricing power of foreign brands [11] - Companies like Ruipuhua and PlaiKe are working to narrow the gap by building their own or partnering with pet hospitals [11][12] - Future trends include a focus on mRNA technology and innovative drug delivery methods, which could reshape the competitive landscape and create larger market opportunities due to the increasing management needs of aging pets [13]

Group 1 - The Shanghai Composite Index has recently surpassed the annual high set on March 18, 2025, and is approaching the high from October 8, 2024, indicating a significant market movement [1] - There is a noticeable divergence among various sectors, with banking, agriculture, personal care, military, chemical, transportation, and petrochemical industries showing a higher proportion of stocks exceeding their March 18, 2025 closing prices [1] - Conversely, sectors such as steel, electronics, home appliances, telecommunications, computers, and electrical equipment have a lower proportion of stocks exceeding their March 18, 2025 levels [1] Group 2 - In the secondary industry analysis, financial (banking, insurance, diversified finance), military (naval equipment, ground weaponry), agriculture (animal health, agricultural products, planting, feed), precious metals, personal care products, and chemical pharmaceuticals show a higher proportion of stocks exceeding their March 18, 2025 closing prices [4] - Sectors like home appliances, electrical equipment, TMT (television broadcasting, communication services, consumer electronics, semiconductors, optical electronics), general steel, and machinery (engineering machinery, automation equipment) have a lower proportion of stocks exceeding their March 18, 2025 levels [4] - Comparing to the October 8, 2024 closing prices, banking, motorcycles, military (ground weaponry, aerospace equipment), chemicals (plastics, non-metallic materials), and new consumption (entertainment products, personal care products, retail, accessories) show a higher proportion of stocks exceeding their previous levels [4]

Investment Rating - The report maintains a "Positive" outlook on the agriculture, forestry, animal husbandry, and fishery sector, indicating it is expected to outperform the overall market [4][5][52]. Core Insights - The report highlights the strong performance of the pig farming sector, with expectations for a re-evaluation of pig prices due to ongoing market dynamics. It emphasizes the importance of quality pig farming enterprises and suggests focusing on the profitability of breeding support and pet food sectors [4][5]. - During the "618" shopping festival, the pet food industry showed resilience, with leading brands performing well. The report suggests that the performance of top companies may exceed expectations throughout the year [4][5]. - The report notes that pig prices have consistently outperformed market expectations since the beginning of 2025, with futures prices remaining lower than spot prices. It anticipates a slow recovery in production capacity and highlights the potential for profit realization in low-cost pig farming [4][5]. Summary by Sections Market Performance - The Shenwan Agriculture, Forestry, Animal Husbandry, and Fishery Index fell by 3.1%, while the CSI 300 Index decreased by 0.5%. The top five gainers included Bangji Technology (up 24.7%) and Chenguang Biotech (up 13.4%), while the top five losers included Andeli (down 18.7%) and Zhongchong Co. (down 13.4%) [4][5][12]. Pig Farming - As of June 22, the average selling price of external three yuan pigs was 14.29 yuan/kg, with a week-on-week increase of 1.2%. The report indicates that the average weight of market pigs decreased to 128.28 kg, down 0.54 kg from the previous week. The report suggests that the expectations of "reducing weight, stabilizing production capacity, and limiting breeding" may lead to a re-evaluation of pig prices in the second half of the year [4][5]. Poultry Farming - The report notes a significant drop in chick prices, with the average price of white feather broiler chicks at 1.72 yuan/chick, down 29.2% week-on-week. The average price of white feather broilers remained stable at 3.52 yuan/kg, with a slight decrease of 1.7% week-on-week [4][5]. Pet Food - The report emphasizes the importance of monitoring the sales performance of pet food during the "618" shopping festival, with a year-on-year increase of 15% in e-commerce sales. The total sales for pet food reached 7.5 billion yuan, up from 5.5 billion yuan in the previous year, indicating a year-on-year growth of 36% [4][5]. Animal Health - The report highlights the recovery in vaccine sales, with a year-on-year increase of 23.02% in the number of veterinary vaccine batches issued in Q1 2025. It suggests that the profitability of breeding enterprises will drive the demand for vaccines and other products [4][5].

农林牧渔行业 超配（维持） 农林牧渔行业双周报（2025/6/6-2025/6/19） 行 业 能繁母猪有望持续去化 2025 年 6 月 20 日 投资要点： 风险提示：疫病大规模爆发，价格下行，自然灾害，市场竞争加剧等。 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 所 分析师：魏红梅 SAC 执业证书编号： S0340513040002 电话：0769-22119462 邮箱：whm2@dgzq.com.cn SW农林牧渔行业跑输沪深300指数。2025年6月6日—2025年6月19日，SW 农林牧渔行业下跌1.11%，跑输同期沪深300指数约0.22个百分点；细分板 块中，仅养殖业录得正收益，上涨1.51%；种植业、动物保健、农产品加 工、渔业和饲料均录得负收益，分别下跌2.15%、2.77%、3.51%、4.15%和 4.92%。估值方面，截至2025年6月19日，SW农林牧渔行业指数整体PB（整 体法，最新报告期，剔除负值）约2.58倍，近两周先回升后回落。目前行 业估值处于行业2006年以来的 ...

Investment Strategy Overview - The report maintains an "outperform" rating for the agriculture, forestry, animal husbandry, and fishery industry, indicating a positive outlook for the sector [3][5][6] Market Performance - From the beginning of 2025 to June 16, the agriculture, forestry, animal husbandry, and fishery index achieved an absolute return of +12.81%, outperforming the CSI 300 index by 14.5 percentage points [10][13] - The pet food sector has shown the highest growth, while the aquatic processing sector has also performed well [13][14] Swine Breeding Sector - The swine breeding industry is expected to enter a phase of simultaneous supply and demand growth in the second half of 2025, driven by a sufficient supply of piglets and an increase in domestic slaughtering due to reduced imports from the U.S. [15][30] - The number of breeding sows and total swine stock remains high, with a notable increase in piglet supply observed from January to April 2025 [18][30] - Major companies like Muyuan Foods have reported significant increases in piglet sales, indicating strong market dynamics [17][30] Animal Health Sector - The animal health market is experiencing steady growth, with a market size increase from 472.29 billion yuan in 2016 to 696.51 billion yuan in 2023, reflecting a compound annual growth rate of 5.71% [35][36] - The introduction of new products and the expansion of demand are driving the growth of the animal health industry, particularly with the anticipated market expansion following the launch of African swine fever vaccines [41][48] Seed Industry - The seed industry is undergoing significant transformation, with a focus on the commercialization of biotechnology breeding, which is expected to enhance market concentration and profitability for related companies [4][16][19] - The regulatory environment is becoming clearer, and companies that have passed initial reviews are now obtaining operational licenses, positioning them to benefit from the industry's growth [4][19] Pet Food Sector - China's pet food market is projected to continue growing, driven by demographic changes and rising living standards, with the market size expected to expand significantly [5][23] - The domestic pet food industry is seeing a shift towards increased online sales and domestic product substitution, indicating a robust growth trajectory [5][23][26] Investment Recommendations - The report suggests focusing on leading companies in the sector, including Muyuan Foods, Pulaike, Qiule Seed Industry, Guai Bao Pet, Zhongchong Co., and Petty Co., as they are expected to benefit from favorable market conditions and valuation recovery [5][32]